Immix Observes Clinical Benefit at Dose-Level 2 in Phase 1b Clinical Trial in Refractory Cancer

LOS ANGELES, /PRNewswire/ --Immix Biopharma, Inc, announced today positive interim results from its ongoing phase 1b/2a study testing IMX-110 in advanced solid tumors. Immix observed Stable Disease at cohort (dose-level) 2 in a middle-aged male with stage IV colorectal cancer that was refractory to radiation therapy, chemotherapy and immunotherapy. The team observed no adverse events at this dose level.

The study is a multiple-ascending dose, Phase 1b clinical trial of IMX-110 to evaluate the compound’s safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with advanced solid tumors and is led by Principal Investigator Prof. Paul de Souza of Western Sydney University, Sydney. Currently, the team is awaiting additional preliminary efficacy readouts from patients in cohorts (dose-levels) 3 and 4, with cohort 5 enrollees set to be recruited imminently. For information about participating in this study, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03382340

The company is also announcing its plans to investigate IMX-109, a nanoformulation of curcumin, in neurodegenerative and age-related diseases, with preliminary human data scheduled to be shared publicly in early 2019.

About IMX-110
IMX-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. IMX-110 contains NF-kB/Stat3/pan-tyrosine kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. IMX-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models — with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin or curcumin alone, and a wholesale shift in the tumor-immune system microenvironment post administration.

About IMX-109
IMX-109 is a nanoformulation of curcumin, a substance with significant preclinical evidence of activity in inflammation-driven and age-related diseases, whose clinical use to-date has been hampered by the poor bioavailability of natural curcumin.

About the Company
Immix Biopharma, Inc. is a clinical-stage, biopharmaceutical company developing therapies for cancer, neurodegenerative and inflammation-driven diseases. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney.

Media Contact

Ryan Witt
+1 (888) 958-1084
info@immixbio.com

For more information and updates, visit: www.immixbio.com.

View original content:http://www.prnewswire.com/news-releases/immix-observes-clinical-benefit-at-dose-level-2-in-phase-1b-clinical-trial-in-refractory-cancer-300762441.html

SOURCE Immix Biopharma, Inc.